

Liping Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3256300/publications.pdf>

Version: 2024-02-01

11

papers

266

citations

1163117

8

h-index

1281871

11

g-index

11

all docs

11

docs citations

11

times ranked

453

citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Pyrrolopyridine- α' -Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5330-5341.	6.4	115
2	Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3946-3950.	2.2	30
3	Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3951-3956.	2.2	22
4	Crystal structures of apo and inhibitor-bound TGF β 2R2 kinase domain: insights into TGF β 2R isoform selectivity. <i>Acta Crystallographica Section D: Structural Biology</i> , 2016, 72, 658-674.	2.3	20
5	Discovery of 4-Azaindole Inhibitors of TGF β 2RI as Immuno-oncology Agents. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1117-1122.	2.8	18
6	Discovery of Non-Nucleotide Small-Molecule STING Agonists <i><math>\text{via}</math></i> Chemotype Hybridization. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3518-3538.	6.4	16
7	Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 288-294.	2.8	15
8	Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5022-5029.	2.2	14
9	Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 494-501.	2.8	10
10	Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1143-1150.	2.8	3
11	Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; N-((R)-1-((cis)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide. <i>Organic Process Research and Development</i> , 2021, 25, 1680-1689.	2.7	3